Sofosbuvir in Treatment of COVID 19

NCT04460443 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-12-08

No results posted yet for this study

Summary

Sofosbuvir containing treatment in treatment of COVID 19 Egyptian patients

Conditions

Interventions

DRUG

sofosbuvir

Sofosbuvir once daily

DRUG

Sofosbuvir ledipsavir

Sofosbuvir ledipsavir once daily

DRUG

Daclatasvir

Daklatasuvir tablets

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Marwa Salama, Consultant · Tanta University - Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-08-01
Completion
2021-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04460443 on ClinicalTrials.gov